DMAA Warnings Shed Light On FDA NDI Enforcement
This article was originally published in The Tan Sheet
FDA’s warning letters to 10 marketers of DMAA-containing products might have a silver lining for the supplement industry as they suggest the agency may be flexible on its controversial interpretation of some provisions in the new dietary ingredient notification requirement.
You may also be interested in...
DoD suspends DMAA sales at military stores after regulators in Canada and New Zealand restricted access and as some U.S. firms change how they market and label the ingredient. These moves and the potential for an FDA review could lead to enforcement against DMAA similar to the 2004 ban against ephedra’s use in supplements.
Identifying possible risks linked to dietary supplements - such as the recalled line of Hydroxycut weight-loss products - is challenging because FDA generally works with post-market information, an agency executive said
FDA is aiming to remove androstenedione supplements from the market by classifying the substance as a new dietary ingredient that has not been the subject of a safety notification to the agency, as required by the Dietary Supplement Health & Education Act